arrow
返回

Pharmacological Strategies to Decrease Long-Term Prescription Opioid Use: A Systematic Review

delete2024-12-19
delete0
delete
OA
AI
H
Hannah Ellerbroek *
G
Gerard A. Kalkman
C
Cornelis Kramers
A
Arnt Schellekens
B
Bart J. F. van den Bemt
DOI:10.3390/jcm13247770delete
delete原文链接
delete分享
delete收藏
查看原文
摘要

摘要

En 中文
Background/Objectives: As long-term prescription opioid use is associated with increased morbidity and mortality, timely dose reduction of prescription opioids should be considered. However, most research has been conducted on patients using heroin. Given the differences between prescription and illicit opioid use, the aim of this review was to provide an overview of pharmacological strategies to reduce prescription opioid use or improve clinical outcomes for people who experience long-term prescription opioid use, including those with opioid use disorder. Methods: We conducted a systematic database search of PubMed, Embase, CINAHL, and the Cochrane Library. Outcomes included dose reduction, treatment dropout, pain, addiction, and outcomes relating to quality of life (depression, functioning, quality of life). Results: We identified thirteen studies (eight randomized controlled trials and five observational studies). Pharmacological strategies were categorized into two categories: (1) deprescribing (tapering) opioids or (2) opioid agonist treatment (OAT) with long-acting opioids. Tapering strategies decreased opioid dosage and had mixed effects on pain and addiction. OAT with buprenorphine or methadone led to improvements in pain relief and quality of life, with a slight (non-significant) preference for methadone in terms of treatment retention (RR = 1.10 [CI: 0.89-1.37]) but not for other outcomes. Most studies had high dropout rates and a serious risk of bias. Conclusions: Tapering reduced prescription opioid doses had mixed effects on pain. OAT improved clinical outcomes without dose reduction. Based on our review findings, there is no clear preference for either tapering or OAT. Tapering may be considered first as it reduces dependency, tolerance, and side effects, but is associated with adverse events and not always feasible. OAT can be a suitable alternative. Non-pharmacological interventions may facilitate tapering. Further research is needed to identify novel pharmacological strategies to facilitate opioid tapering. Registration: PROSPERO 2022 CRD42022323468.
Keyword:
prescription opioids
prescription opioid use disorder
prescription opioid misuse
opioid tapering
opioid rotation
opioid agonist treatment
AI总结

AI总结

对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。

期刊

Journal of Clinical Medicine 封面图
Journal of Clinical Medicine
IF:
2.9
论文数:
5.2W
被引数:
9.8W

机构

R
Radboud University Nijmegen
学者数:
4.4W
论文数: 3.4W
被引数: 5.4W
引用论文

引用论文

Scaled-Up Ocean Injection of CO2–Hydrate Composite Particles†
err2007-11-01
err0
PREAI
errC. Tsouris; P. Szymcek; P. Taboada-Serrano; S. D. McCallum; P. Brewer; E. Peltzer; P. Walz; E. Adams; A. Chow; W. K. Johnson; J. Summers
err分享
err收藏
A Clinical Trial Comparing Tapering Doses of Buprenorphine With Steady Doses for Chronic Pain and Coexistent Opioid Addiction
err2010-09-01
err46
errOAAI
errBlondell, Richard D.; Ashrafioun, Lisham; Dambra, Christina M.; Foschio, Elisa M.; Zielinski, Amy L.; Salcedo, Daniel M.
err分享
err收藏
The relationship of MicroRNA-21 and plaque stability in acute coronary syndrome
err2019-11-01
err0
errOAAI
errWangwei He; Liyuan Zhu; Yu Huang; Yinfen Zhang; Weimin Shen; Lihuan Fang; Jun Li; Zhuo Wang; Qiang Xie
err分享
err收藏
Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: A two-phase randomized controlled trial
err2013-11-01
err29
errOAAI
errLofwall, Michelle R.; Babalonis, Shanna; Nuzzo, Paul A.; Siegel, Anthony; Campbell, Charles; Walsh, Sharon L.
err分享
err收藏
学者 查看更多内容